Bank Julius Baer & Co. Ltd, Zurich Medicinova Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.13 - $2.1 $1,181 - $2,196	-1,046 Reduced 6.13%	16,027 $33,000
Q2 2024 Aug 14, 2024	SELL	$1.28 - $1.57 $2,466 - $3,025	-1,927 Reduced 10.14%	17,073 $24,000
Q4 2023 Feb 02, 2024	BUY	$1.38 - $2.06 $26,219 - $39,140	19,000 New	19,000 $28,000
Q2 2023 Jul 24, 2023	BUY	$2.09 - $2.43 $38,978 - $45,319	18,650 New	18,650 $43,000
Q4 2022 Jan 24, 2023	BUY	$1.97 - $2.66 $591 - $798	300 Added 1.6%	19,000 $39,000
Q3 2022 Nov 04, 2022	SELL	$2.1 - $2.6 $630 - $780	-300 Reduced 1.58%	18,700 $41,000
Q4 2021 Feb 15, 2022	BUY	$2.61 - $4.42 $49,590 - $83,980	19,000 New	19,000 $51,000

4.96M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $90.2M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.